FDA leaders are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency's decisions from public scrutiny. The FDA "would like to get away" from assembling panels of experts to examine and vote on individual drugs, because "I don't think they're needed," said George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research. He relayed the message at a meeting of health care product makers and to an FDA advocacy group. In addition to being redundant, Tidmarsh whined, advisory meetings on specific drugs were "a tremendous amount of work for the company and for the FDA. We want to use that work and our time to focus on the big questions."